D., & Edden, R
PlexusDx compounded medications cost significantly less because they're manufactured by licensed 503A compounding pharmacies rather than multinational pharmaceutical companies
While providing local GI benefits, BPC-157 demonstrates systemic bioavailability after oral administration, distributing throughout the body to support healing in joints, tendons, muscles, and other tissues
MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
Small 19 (49), e2303459
